805 related articles for article (PubMed ID: 25684751)
21. Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice.
Nencioni A; da Silva RF; Fraga-Silva RA; Steffens S; Fabre M; Bauer I; Caffa I; Magnone M; Sociali G; Quercioli A; Pelli G; Lenglet S; Galan K; Burger F; Vázquez Calvo S; Bertolotto M; Bruzzone S; Ballestrero A; Patrone F; Dallegri F; Santos RA; Stergiopulos N; Mach F; Vuilleumier N; Montecucco F
Thromb Haemost; 2014 Feb; 111(2):308-22. PubMed ID: 24196571
[TBL] [Abstract][Full Text] [Related]
22. Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation.
Okumura S; Sasaki T; Minami Y; Ohsaki Y
J Thorac Oncol; 2012 Jan; 7(1):49-56. PubMed ID: 22089115
[TBL] [Abstract][Full Text] [Related]
23. Nicotinamide phosphoribosyltransferase may be involved in age-related brain diseases.
Liu LY; Wang F; Zhang XY; Huang P; Lu YB; Wei EQ; Zhang WP
PLoS One; 2012; 7(10):e44933. PubMed ID: 23071504
[TBL] [Abstract][Full Text] [Related]
24. EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells.
Mutz CN; Schwentner R; Aryee DNT; Bouchard EDJ; Mejia EM; Hatch GM; Kauer MO; Katschnig AM; Ban J; Garten A; Alonso J; Banerji V; Kovar H
Oncotarget; 2017 Apr; 8(15):24679-24693. PubMed ID: 28160567
[TBL] [Abstract][Full Text] [Related]
25. Anti-proliferation effect of APO866 on C6 glioblastoma cells by inhibiting nicotinamide phosphoribosyltransferase.
Zhang LY; Liu LY; Qie LL; Ling KN; Xu LH; Wang F; Fang SH; Lu YB; Hu H; Wei EQ; Zhang WP
Eur J Pharmacol; 2012 Jan; 674(2-3):163-70. PubMed ID: 22119381
[TBL] [Abstract][Full Text] [Related]
26. EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition.
Zucal C; D'Agostino VG; Casini A; Mantelli B; Thongon N; Soncini D; Caffa I; Cea M; Ballestrero A; Quattrone A; Indraccolo S; Nencioni A; Provenzani A
BMC Cancer; 2015 Nov; 15():855. PubMed ID: 26542945
[TBL] [Abstract][Full Text] [Related]
27. Targeting the NAD
Ye C; Qi L; Li X; Wang J; Yu J; Zhou B; Guo C; Chen J; Zheng S
Cell Commun Signal; 2020 Jan; 18(1):16. PubMed ID: 32005247
[TBL] [Abstract][Full Text] [Related]
28. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
Ju HQ; Zhuang ZN; Li H; Tian T; Lu YX; Fan XQ; Zhou HJ; Mo HY; Sheng H; Chiao PJ; Xu RH
Cancer Lett; 2016 Aug; 379(1):1-11. PubMed ID: 27233476
[TBL] [Abstract][Full Text] [Related]
29. Nicotinamide mononucleotide, an intermediate of NAD+ synthesis, protects the heart from ischemia and reperfusion.
Yamamoto T; Byun J; Zhai P; Ikeda Y; Oka S; Sadoshima J
PLoS One; 2014; 9(6):e98972. PubMed ID: 24905194
[TBL] [Abstract][Full Text] [Related]
30. Monocyte-derived extracellular Nampt-dependent biosynthesis of NAD(+) protects the heart against pressure overload.
Yano M; Akazawa H; Oka T; Yabumoto C; Kudo-Sakamoto Y; Kamo T; Shimizu Y; Yagi H; Naito AT; Lee JK; Suzuki J; Sakata Y; Komuro I
Sci Rep; 2015 Nov; 5():15857. PubMed ID: 26522369
[TBL] [Abstract][Full Text] [Related]
31. Nicotinamide mononucleotide attenuates brain injury after intracerebral hemorrhage by activating Nrf2/HO-1 signaling pathway.
Wei CC; Kong YY; Li GQ; Guan YF; Wang P; Miao CY
Sci Rep; 2017 Apr; 7(1):717. PubMed ID: 28386082
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of NAMPT markedly enhances plasma-activated medium-induced cell death in human breast cancer MDA-MB-231 cells.
Nagaya M; Hara H; Kamiya T; Adachi T
Arch Biochem Biophys; 2019 Nov; 676():108155. PubMed ID: 31628926
[TBL] [Abstract][Full Text] [Related]
33. The NAMPT inhibitor FK866 reverts the damage in spinal cord injury.
Esposito E; Impellizzeri D; Mazzon E; Fakhfouri G; Rahimian R; Travelli C; Tron GC; Genazzani AA; Cuzzocrea S
J Neuroinflammation; 2012 Apr; 9():66. PubMed ID: 22490786
[TBL] [Abstract][Full Text] [Related]
34. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.
Cea M; Cagnetta A; Fulciniti M; Tai YT; Hideshima T; Chauhan D; Roccaro A; Sacco A; Calimeri T; Cottini F; Jakubikova J; Kong SY; Patrone F; Nencioni A; Gobbi M; Richardson P; Munshi N; Anderson KC
Blood; 2012 Oct; 120(17):3519-29. PubMed ID: 22955917
[TBL] [Abstract][Full Text] [Related]
35. Nicotinamide phosphoribosyltransferase (NAMPT) activity is essential for survival of resting lymphocytes.
Pittelli M; Cavone L; Lapucci A; Oteri C; Felici R; Niccolai E; Amedei A; Chiarugi A
Immunol Cell Biol; 2014 Feb; 92(2):191-9. PubMed ID: 24275857
[TBL] [Abstract][Full Text] [Related]
36. Targeting NAD immunometabolism limits severe graft-versus-host disease and has potent antileukemic activity.
Gerner RR; Macheiner S; Reider S; Siegmund K; Grabherr F; Mayr L; Texler B; Moser P; Effenberger M; Schwaighofer H; Moschen AR; Kircher B; Oberacher H; Zeiser R; Tilg H; Nachbaur D
Leukemia; 2020 Jul; 34(7):1885-1897. PubMed ID: 31974433
[TBL] [Abstract][Full Text] [Related]
37. Up-regulation of nicotinamide phosphoribosyltransferase and increase of NAD+ levels by glucose restriction extend replicative lifespan of human fibroblast Hs68 cells.
Yang NC; Song TY; Chang YZ; Chen MY; Hu ML
Biogerontology; 2015 Feb; 16(1):31-42. PubMed ID: 25146190
[TBL] [Abstract][Full Text] [Related]
38. On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells.
Gehrke I; Bouchard ED; Beiggi S; Poeppl AG; Johnston JB; Gibson SB; Banerji V
Clin Cancer Res; 2014 Sep; 20(18):4861-72. PubMed ID: 25172933
[TBL] [Abstract][Full Text] [Related]
39. Nicotinamide phosphoribosyltransferase inhibitor ameliorates mouse aging-induced cognitive impairment.
Zeng M; Wei TF; Chen C; Shen C; Gao TY; Xie X; Wu M; Lu YB; Zhang WP
J Cereb Blood Flow Metab; 2021 Oct; 41(10):2510-2523. PubMed ID: 33818184
[TBL] [Abstract][Full Text] [Related]
40. A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT.
Barraud M; Garnier J; Loncle C; Gayet O; Lequeue C; Vasseur S; Bian B; Duconseil P; Gilabert M; Bigonnet M; Maignan A; Moutardier V; Garcia S; Turrini O; Delpero JR; Giovannini M; Grandval P; Gasmi M; Ouaissi M; Secq V; Poizat F; Guibert N; Iovanna J; Dusetti N
Oncotarget; 2016 Aug; 7(33):53783-53796. PubMed ID: 27462772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
